Wild-type RAS Metastatic Colorectal Cancer
Conditions
Keywords
Wild-type RAS, Metastatic Colorectal Cancer, Vectibix
Brief summary
The primary objective was to describe the pattern of use of panitumumab (Vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
Interventions
OTHERPanitumumab + Chemotherapy
Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
Sponsors
Amgen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject is ≥ 18 years of age at date of enrolment * Histologically or cytologically confirmed carcinoma of colon or rectum * Subject with metastatic carcinoma of colon or rectum * Confirmed wild-type RAS status of tumour * Subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available * Tumour assessment (ie, computed tomography \[CT\]/magnetic resonance imaging \[MRI\]) within 12 weeks (84 days) prior to first Vectibix® infusion. * Subjects treated with at least one infusion of Vectibix® in combination with chemotherapy a maximum of 84 days before entering study: first-line in combination with FOLFOX (folinic acid, leucovorin, fluorouracil \[5FU\], oxaliplatin) or second-line in combination with FOLFIRI (folinic acid, leucovorin, 5FU, irinotecan) in subjects who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type RAS mCRC per approved prescribing information * Subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) * Subjects treated with Vectibix® in accordance with the current version of the Summary of Product Characteristics (SmPC)
Exclusion criteria
* Ongoing or planned concurrent participation in any clinical study involving Investigational Product that has not been approved by the European Medicines Agency for any indication * Ongoing or planned concurrent participation in any clinical study where the dosing of Vectibix® is determined by the protocol (participation in clinical trials on an approved drug and observational trials are permitted but these cannot mandate how mCRC should be treated)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay | 12 months | — |
| Maximum Dose of Panitumumab | 12 months | — |
| Duration of Panitumumab Exposure | 12 months | Duration of exposure is the time from the first to the last panitumumab infusion |
| Mean Interval Between Panitumumab Infusions | 12 months | — |
| Percentage of Participants With at Least One Panitumumab Dose Reduction | 12 months | — |
| Percentage of Participants With at Least One Panitumumab Dose Delay | 12 months | — |
| Reasons for Discontinuation of Panitumumab | 12 months | — |
| Duration of Exposure of All Concomitant Chemotherapy | 12 months | Duration of exposure is the time from the first date to the last date of chemotherapy administration. |
| Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction | 12 months | — |
| Total Number of Panitumumab Infusions | 12 months | — |
| Cumulative Dose of Panitumumab | 12 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Hospital Stay | 12 months | — |
| Number of Participants With at Least One Hospitalization | 12 months | — |
| Reasons for Hospitalization | 12 months | Participants may have had more than one hospital visit and/or reason for a hospital visit. |
| Percentage of Participants With an Overall Response | 12 months | Tumor response was assessed by the investigator using standard radiological imaging. Overall response is defined as a best tumor response of complete response or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST). |
| Number of Participants With Resectability | 12 months | Resectability denotes whether a participant became resectable during the study. |
| Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation | 12 months | — |
| Type of Post-Panitumumab Anti-cancer Treatment | 12 months | Participants may have received more than one type of anti-cancer treatment that was initiated after panitumumab discontinuation. |
| Types of Hospital Visit | 12 months | Participants may have had more than one type of hospital visit. |
Participant flow
Recruitment details
The study was conducted in France and Germany between 10 December 2012 and 30 November 2016.
Participants by arm
| Arm | Count |
|---|---|
| Panitumumab + FOLFOX First-line Participants with metastatic colorectal cancer (mCRC) with tumor expressing wild-type RAS who received panitumumab in combination with FOLFOX as first-line treatment (FLFAS). | 164 |
| Panitumumab + FOLFIRI Second-line Participants with mCRC with tumor expressing wild-type RAS who received panitumumab in combination with FOLFIRI as second-line treatment and received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) (SLFAS). | 37 |
| Panitumumab + FOLFIRI First-line Participants with mCRC with tumor expressing wild-type RAS who received panitumumab in combination with FOLFIRI as first-line treatment (FLFFAS). | 12 |
| Total | 213 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Administrative Decision | 8 | 2 | 1 |
| Overall Study | Death | 13 | 4 | 1 |
| Overall Study | Discontinued Panitumumab Treatment | 106 | 25 | 7 |
| Overall Study | Lost to Follow-up | 7 | 1 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Panitumumab + FOLFOX First-line | Panitumumab + FOLFIRI Second-line | Panitumumab + FOLFIRI First-line | Total |
|---|---|---|---|---|
| Age, Continuous | 64.8 years STANDARD_DEVIATION 9.6 | 65.8 years STANDARD_DEVIATION 9.9 | 69.0 years STANDARD_DEVIATION 7.6 | 65.2 years STANDARD_DEVIATION 9.5 |
| Age, Customized ≥ 65 to < 75 years | 68 Participants | 14 Participants | 7 Participants | 89 Participants |
| Age, Customized < 65 years | 73 Participants | 18 Participants | 2 Participants | 93 Participants |
| Age, Customized ≥ 75 years | 23 Participants | 5 Participants | 3 Participants | 31 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - Fully active | 44 Participants | 7 Participants | 4 Participants | 55 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 - Restricted but ambulatory | 28 Participants | 11 Participants | 3 Participants | 42 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 2 - Ambulatory but unable to work | 8 Participants | 2 Participants | 0 Participants | 10 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Missing | 84 Participants | 17 Participants | 5 Participants | 106 Participants |
| Metastatic Colorectal Cancer Status Metachronous | 39 Participants | 14 Participants | 7 Participants | 60 Participants |
| Metastatic Colorectal Cancer Status Missing | 9 Participants | 2 Participants | 0 Participants | 11 Participants |
| Metastatic Colorectal Cancer Status Synchronous | 115 Participants | 20 Participants | 5 Participants | 140 Participants |
| Metastatic Colorectal Cancer Status Unknown | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Metastatic Disease Lesion Sites Liver | 123 participants | 25 participants | 5 participants | 153 participants |
| Metastatic Disease Lesion Sites Lung | 36 participants | 13 participants | 4 participants | 53 participants |
| Metastatic Disease Lesion Sites Other | 56 participants | 11 participants | 4 participants | 71 participants |
| Primary Colorectal Cancer Type Colon | 3 Participants | 2 Participants | 0 Participants | 5 Participants |
| Primary Colorectal Cancer Type Colon, left of mid-line | 54 Participants | 14 Participants | 4 Participants | 72 Participants |
| Primary Colorectal Cancer Type Colon, right of mid-line | 41 Participants | 8 Participants | 7 Participants | 56 Participants |
| Primary Colorectal Cancer Type Rectum | 66 Participants | 13 Participants | 1 Participants | 80 Participants |
| Sex: Female, Male Female | 52 Participants | 13 Participants | 5 Participants | 70 Participants |
| Sex: Female, Male Male | 112 Participants | 24 Participants | 7 Participants | 143 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 164 | 0 / 37 | 0 / 12 |
| other Total, other adverse events | 101 / 164 | 25 / 37 | 8 / 12 |
| serious Total, serious adverse events | 10 / 164 | 0 / 37 | 0 / 12 |
Outcome results
Primary
Cumulative Dose of Panitumumab
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Cumulative Dose of Panitumumab | 4262.5 mg |
| Panitumumab + FOLFIRI Second-line | Cumulative Dose of Panitumumab | 4000.0 mg |
| Panitumumab + FOLFIRI First-line | Cumulative Dose of Panitumumab | 3782.5 mg |
Primary
Duration of Exposure of All Concomitant Chemotherapy
Duration of exposure is the time from the first date to the last date of chemotherapy administration.
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Duration of Exposure of All Concomitant Chemotherapy | 5.240 months |
| Panitumumab + FOLFIRI Second-line | Duration of Exposure of All Concomitant Chemotherapy | 5.092 months |
| Panitumumab + FOLFIRI First-line | Duration of Exposure of All Concomitant Chemotherapy | 3.860 months |
Primary
Duration of Panitumumab Exposure
Duration of exposure is the time from the first to the last panitumumab infusion
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Duration of Panitumumab Exposure | 5.339 months |
| Panitumumab + FOLFIRI Second-line | Duration of Panitumumab Exposure | 6.012 months |
| Panitumumab + FOLFIRI First-line | Duration of Panitumumab Exposure | 5.339 months |
Primary
Maximum Dose of Panitumumab
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Maximum Dose of Panitumumab | 450.0 mg |
| Panitumumab + FOLFIRI Second-line | Maximum Dose of Panitumumab | 420.0 mg |
| Panitumumab + FOLFIRI First-line | Maximum Dose of Panitumumab | 507.0 mg |
Primary
Mean Interval Between Panitumumab Infusions
Time frame: 12 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Mean Interval Between Panitumumab Infusions | > 21 to 28 days | 21 Participants |
| Panitumumab + FOLFOX First-line | Mean Interval Between Panitumumab Infusions | > 14 to 21 days | 98 Participants |
| Panitumumab + FOLFOX First-line | Mean Interval Between Panitumumab Infusions | > 0 to 7 days | 0 Participants |
| Panitumumab + FOLFOX First-line | Mean Interval Between Panitumumab Infusions | > 7 to 14 days | 38 Participants |
| Panitumumab + FOLFOX First-line | Mean Interval Between Panitumumab Infusions | > 28 days | 6 Participants |
| Panitumumab + FOLFIRI Second-line | Mean Interval Between Panitumumab Infusions | > 14 to 21 days | 22 Participants |
| Panitumumab + FOLFIRI Second-line | Mean Interval Between Panitumumab Infusions | > 0 to 7 days | 0 Participants |
| Panitumumab + FOLFIRI Second-line | Mean Interval Between Panitumumab Infusions | > 7 to 14 days | 7 Participants |
| Panitumumab + FOLFIRI Second-line | Mean Interval Between Panitumumab Infusions | > 21 to 28 days | 8 Participants |
| Panitumumab + FOLFIRI Second-line | Mean Interval Between Panitumumab Infusions | > 28 days | 0 Participants |
| Panitumumab + FOLFIRI First-line | Mean Interval Between Panitumumab Infusions | > 28 days | 1 Participants |
| Panitumumab + FOLFIRI First-line | Mean Interval Between Panitumumab Infusions | > 21 to 28 days | 5 Participants |
| Panitumumab + FOLFIRI First-line | Mean Interval Between Panitumumab Infusions | > 0 to 7 days | 0 Participants |
| Panitumumab + FOLFIRI First-line | Mean Interval Between Panitumumab Infusions | > 14 to 21 days | 4 Participants |
| Panitumumab + FOLFIRI First-line | Mean Interval Between Panitumumab Infusions | > 7 to 14 days | 2 Participants |
Primary
Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay | 29.3 percentage of participants |
| Panitumumab + FOLFIRI Second-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay | 29.7 percentage of participants |
| Panitumumab + FOLFIRI First-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay | 33.3 percentage of participants |
Primary
Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction | 43.3 percentage of participants |
| Panitumumab + FOLFIRI Second-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction | 24.3 percentage of participants |
| Panitumumab + FOLFIRI First-line | Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction | 58.3 percentage of participants |
Primary
Percentage of Participants With at Least One Panitumumab Dose Delay
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Percentage of Participants With at Least One Panitumumab Dose Delay | 42.7 percentage of participants |
| Panitumumab + FOLFIRI Second-line | Percentage of Participants With at Least One Panitumumab Dose Delay | 21.6 percentage of participants |
| Panitumumab + FOLFIRI First-line | Percentage of Participants With at Least One Panitumumab Dose Delay | 41.7 percentage of participants |
Primary
Percentage of Participants With at Least One Panitumumab Dose Reduction
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Percentage of Participants With at Least One Panitumumab Dose Reduction | 36.6 percentage of participants |
| Panitumumab + FOLFIRI Second-line | Percentage of Participants With at Least One Panitumumab Dose Reduction | 21.6 percentage of participants |
| Panitumumab + FOLFIRI First-line | Percentage of Participants With at Least One Panitumumab Dose Reduction | 50.0 percentage of participants |
Primary
Reasons for Discontinuation of Panitumumab
Time frame: 12 months
Population: Participants who discontinued panitumumab while on study
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Disease progression | 35 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Physician or Oncologist decision | 30 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Planned surgical resection | 16 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Death | 12 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Adverse Drug Reaction (ADR) | 11 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue all treatment | 9 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Adverse event | 8 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Lost to follow-up | 6 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Other | 6 Participants |
| Panitumumab + FOLFOX First-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue panitumumab | 5 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Other | 1 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Disease progression | 12 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue all treatment | 1 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Adverse Drug Reaction (ADR) | 4 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Physician or Oncologist decision | 7 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue panitumumab | 3 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Lost to follow-up | 1 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Planned surgical resection | 1 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Adverse event | 1 Participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Discontinuation of Panitumumab | Death | 3 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Lost to follow-up | 0 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Death | 1 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Adverse Drug Reaction (ADR) | 2 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue all treatment | 2 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Other | 0 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Adverse event | 0 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Disease progression | 3 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Patient request to discontinue panitumumab | 0 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Physician or Oncologist decision | 0 Participants |
| Panitumumab + FOLFIRI First-line | Reasons for Discontinuation of Panitumumab | Planned surgical resection | 0 Participants |
Primary
Total Number of Panitumumab Infusions
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Total Number of Panitumumab Infusions | 10.0 infusions |
| Panitumumab + FOLFIRI Second-line | Total Number of Panitumumab Infusions | 10.0 infusions |
| Panitumumab + FOLFIRI First-line | Total Number of Panitumumab Infusions | 8.0 infusions |
Secondary
Duration of Hospital Stay
Time frame: 12 months
Population: Participants with at least one hospital visit
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Duration of Hospital Stay | 40.0 days |
| Panitumumab + FOLFIRI Second-line | Duration of Hospital Stay | 28.0 days |
| Panitumumab + FOLFIRI First-line | Duration of Hospital Stay | 24.5 days |
Secondary
Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation | 84 participants |
| Panitumumab + FOLFIRI Second-line | Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation | 15 participants |
| Panitumumab + FOLFIRI First-line | Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation | 3 participants |
Secondary
Number of Participants With at Least One Hospitalization
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Number of Participants With at Least One Hospitalization | 163 Participants |
| Panitumumab + FOLFIRI Second-line | Number of Participants With at Least One Hospitalization | 37 Participants |
| Panitumumab + FOLFIRI First-line | Number of Participants With at Least One Hospitalization | 12 Participants |
Secondary
Number of Participants With Resectability
Resectability denotes whether a participant became resectable during the study.
Time frame: 12 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Number of Participants With Resectability | No | 135 Participants |
| Panitumumab + FOLFOX First-line | Number of Participants With Resectability | Yes | 20 Participants |
| Panitumumab + FOLFOX First-line | Number of Participants With Resectability | Unknown | 9 Participants |
| Panitumumab + FOLFIRI Second-line | Number of Participants With Resectability | No | 33 Participants |
| Panitumumab + FOLFIRI Second-line | Number of Participants With Resectability | Yes | 3 Participants |
| Panitumumab + FOLFIRI Second-line | Number of Participants With Resectability | Unknown | 1 Participants |
| Panitumumab + FOLFIRI First-line | Number of Participants With Resectability | Yes | 1 Participants |
| Panitumumab + FOLFIRI First-line | Number of Participants With Resectability | Unknown | 4 Participants |
| Panitumumab + FOLFIRI First-line | Number of Participants With Resectability | No | 7 Participants |
Secondary
Percentage of Participants With an Overall Response
Tumor response was assessed by the investigator using standard radiological imaging. Overall response is defined as a best tumor response of complete response or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST).
Time frame: 12 months
Population: Participants with tumor response data post-baseline
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Panitumumab + FOLFOX First-line | Percentage of Participants With an Overall Response | 47.6 percentage of participants |
| Panitumumab + FOLFIRI Second-line | Percentage of Participants With an Overall Response | 33.3 percentage of participants |
| Panitumumab + FOLFIRI First-line | Percentage of Participants With an Overall Response | 50.0 percentage of participants |
Secondary
Reasons for Hospitalization
Participants may have had more than one hospital visit and/or reason for a hospital visit.
Time frame: 12 months
Population: Participants with at least one hospitalization
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Reasons for Hospitalization | Treatment-related | 88 participants |
| Panitumumab + FOLFOX First-line | Reasons for Hospitalization | mCRC related | 144 participants |
| Panitumumab + FOLFOX First-line | Reasons for Hospitalization | mCRC and treatment related | 74 participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Hospitalization | Treatment-related | 16 participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Hospitalization | mCRC related | 30 participants |
| Panitumumab + FOLFIRI Second-line | Reasons for Hospitalization | mCRC and treatment related | 14 participants |
| Panitumumab + FOLFIRI First-line | Reasons for Hospitalization | mCRC related | 10 participants |
| Panitumumab + FOLFIRI First-line | Reasons for Hospitalization | mCRC and treatment related | 7 participants |
| Panitumumab + FOLFIRI First-line | Reasons for Hospitalization | Treatment-related | 9 participants |
Secondary
Type of Post-Panitumumab Anti-cancer Treatment
Participants may have received more than one type of anti-cancer treatment that was initiated after panitumumab discontinuation.
Time frame: 12 months
Population: Participants who reported use of anti-cancer treatment after discontinuation of panitumumab
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Type of Post-Panitumumab Anti-cancer Treatment | Targeted biologics | 5 participants |
| Panitumumab + FOLFOX First-line | Type of Post-Panitumumab Anti-cancer Treatment | Radiotherapy | 5 participants |
| Panitumumab + FOLFOX First-line | Type of Post-Panitumumab Anti-cancer Treatment | Chemotherapy | 72 participants |
| Panitumumab + FOLFOX First-line | Type of Post-Panitumumab Anti-cancer Treatment | Other | 10 participants |
| Panitumumab + FOLFOX First-line | Type of Post-Panitumumab Anti-cancer Treatment | Other small molecules | 0 participants |
| Panitumumab + FOLFIRI Second-line | Type of Post-Panitumumab Anti-cancer Treatment | Radiotherapy | 0 participants |
| Panitumumab + FOLFIRI Second-line | Type of Post-Panitumumab Anti-cancer Treatment | Chemotherapy | 10 participants |
| Panitumumab + FOLFIRI Second-line | Type of Post-Panitumumab Anti-cancer Treatment | Other | 2 participants |
| Panitumumab + FOLFIRI Second-line | Type of Post-Panitumumab Anti-cancer Treatment | Targeted biologics | 3 participants |
| Panitumumab + FOLFIRI Second-line | Type of Post-Panitumumab Anti-cancer Treatment | Other small molecules | 1 participants |
| Panitumumab + FOLFIRI First-line | Type of Post-Panitumumab Anti-cancer Treatment | Other small molecules | 0 participants |
| Panitumumab + FOLFIRI First-line | Type of Post-Panitumumab Anti-cancer Treatment | Targeted biologics | 1 participants |
| Panitumumab + FOLFIRI First-line | Type of Post-Panitumumab Anti-cancer Treatment | Chemotherapy | 3 participants |
| Panitumumab + FOLFIRI First-line | Type of Post-Panitumumab Anti-cancer Treatment | Radiotherapy | 1 participants |
| Panitumumab + FOLFIRI First-line | Type of Post-Panitumumab Anti-cancer Treatment | Other | 0 participants |
Secondary
Types of Hospital Visit
Participants may have had more than one type of hospital visit.
Time frame: 12 months
Population: Participants with at least one hospital visit
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Panitumumab + FOLFOX First-line | Types of Hospital Visit | Day case | 6 participants |
| Panitumumab + FOLFOX First-line | Types of Hospital Visit | Outpatient | 157 participants |
| Panitumumab + FOLFOX First-line | Types of Hospital Visit | Inpatient | 75 participants |
| Panitumumab + FOLFOX First-line | Types of Hospital Visit | Emergency room | 11 participants |
| Panitumumab + FOLFOX First-line | Types of Hospital Visit | Other | 6 participants |
| Panitumumab + FOLFIRI Second-line | Types of Hospital Visit | Inpatient | 12 participants |
| Panitumumab + FOLFIRI Second-line | Types of Hospital Visit | Other | 1 participants |
| Panitumumab + FOLFIRI Second-line | Types of Hospital Visit | Emergency room | 1 participants |
| Panitumumab + FOLFIRI Second-line | Types of Hospital Visit | Day case | 2 participants |
| Panitumumab + FOLFIRI Second-line | Types of Hospital Visit | Outpatient | 35 participants |
| Panitumumab + FOLFIRI First-line | Types of Hospital Visit | Outpatient | 12 participants |
| Panitumumab + FOLFIRI First-line | Types of Hospital Visit | Inpatient | 6 participants |
| Panitumumab + FOLFIRI First-line | Types of Hospital Visit | Day case | 0 participants |
| Panitumumab + FOLFIRI First-line | Types of Hospital Visit | Other | 0 participants |
| Panitumumab + FOLFIRI First-line | Types of Hospital Visit | Emergency room | 0 participants |